查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1613312

树突细胞癌疫苗市场：依癌症类型、最终用途划分 - 2025-2030 年全球预测

Dendritic Cell Cancer Vaccine Market by Cancer Type (Breast Cancer, Liver Cancer, Lung Cancer), End-use (Hospitals, Research Institutes, Specialty Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年树突状细胞癌疫苗市场规模为35,006万美元，预计2024年将达3,9,259万美元，复合年增长率为13.05%，2030年将达8,2649万美元，预计将达1000万美元。

树突细胞癌症疫苗市场围绕着肿瘤学一个有前途的领域：旨在利用树突状细胞刺激免疫系统攻击癌细胞的疫苗。这些疫苗代表了针对多种癌症类型的癌症免疫疗法的创新方法，包括黑色素瘤、前列腺癌和神经胶母细胞瘤。这些疫苗的需求源于对比化疗和放射线治疗等传统治疗方法副作用较少的更有效的癌症疗法的需求。最终用途涵盖各种癌症阶段和类型，反映了世界各地肿瘤学和先进临床研究设施的广泛最终用途。推动市场开拓的主要因素是生物技术的进步、癌症发生率的增加以及医疗机构研发投资的增加。生物技术公司和研发机构之间的合作促进创新产品开发并为客製化癌症疫苗铺平道路，这是一个巨大的商机。鼓励公司专注于个人化医疗的创新，并探索与人工智慧技术提供者的合作伙伴关係，以加强疫苗开发流程。另一方面，市场开拓面临的挑战包括开发成本高、监管条件严格以及世界某些地区的认知度低。此外，临床试验的复杂性和患者反应的可变性构成了主要障碍。然而，由于医疗基础设施的扩大和癌症发病率的上升，新兴市场的潜力开拓。创新研究领域包括透过联合治疗和在疫苗配方中使用奈米技术来提高疫苗功效。该市场本质上充满活力且快速发展，为投资尖端研究、策略联盟和高效供应链管理的公司提供了巨大的成长潜力。透过抓住这些机会并克服现有障碍，公司可以有效地为推进全球癌症治疗方法和改善患者治疗结果做出贡献。

主要市场统计
基准年[2023] 35006万美元
预计年份 [2024] 3.9259 亿美元
预测年份 [2030] 8.2649亿美元
复合年增长率（%） 13.05%

市场动态：快速发展的树突状细胞癌疫苗市场的关键市场洞察

树突状细胞癌疫苗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球癌症患者数量增加
    • 免疫疗法和个人化医疗的持续进步
  • 市场限制因素
    • 树突细胞疫苗技术开发成本高
  • 市场机会
    • 树突细胞生物学和疫苗技术领域的研发不断增加
    • 加速癌症治疗开发的支持性法规结构
  • 市场挑战
    • 对树突细胞疫苗技术的好处认识不足

波特五力：驾驭树突细胞癌疫苗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解树突状细胞癌疫苗市场的外部影响

外部宏观环境因素在塑造树突状细胞癌疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解树突细胞癌疫苗市场的竞争状况

对树突状细胞癌疫苗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵树突状细胞癌疫苗市场供应商绩效评估

FPNV定位矩阵是评估树突状细胞癌疫苗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了树突状细胞癌疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对树突状细胞癌疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症发生率增加
      • 免疫疗法和个人化医疗的持续进步
    • 抑制因素
      • 树突细胞疫苗技术开发成本高
    • 机会
      • 加大树突细胞生物学和疫苗技术领域的研发力度
      • 加速癌症治疗开发的支持性法规结构
    • 任务
      • 对树突细胞疫苗技术优势的认识有限
  • 市场区隔分析
    • 癌症类型：特异性针对癌细胞的前列腺癌树突状细胞癌疫苗的潜力不断增长
    • 最终用途：在医院综合护理设施中增加树突状细胞癌疫苗的使用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章树突细胞癌疫苗市场：依癌症类型

  • 乳癌
  • 肝癌
  • 肺癌
  • 卵巢癌
  • 胰臟癌
  • 摄护腺癌

第七章树突细胞癌疫苗市场：依最终用途分类

  • 医院
  • 调查机构
  • 专科诊所

第八章美洲树突细胞癌疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区树突细胞癌疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲树突细胞癌疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • BioNTech 开始基于 mRNA 的个人化新抗原特异性免疫疗法的 2 期试验，扩大后期临床肿瘤学产品组合
  • 战略分析和建议

公司名单

  • Aduro Biotech
  • APAC Biotech
  • Argos Therapeutics
  • Batavia Biosciences BV
  • Creative Biolabs
  • Dendreon Pharmaceuticals
  • GSK PLC
  • ImmunoCellular Therapeutics
  • JW CreaGene
  • Northwest Biotherapeutics
  • Northwest Biotherapeutics, Inc.
  • Nouscom
Product Code: MRR-351BAD503B28

The Dendritic Cell Cancer Vaccine Market was valued at USD 350.06 million in 2023, expected to reach USD 392.59 million in 2024, and is projected to grow at a CAGR of 13.05%, to USD 826.49 million by 2030.

The Dendritic Cell Cancer Vaccine market revolves around a promising field in oncology where vaccines are designed to use dendritic cells to stimulate the immune system to attack cancer cells. These vaccines represent an innovative approach to cancer immunotherapy, targeting various cancer types including melanoma, prostate, and glioblastoma. The necessity of these vaccines arises from the need for more effective cancer treatments with fewer side effects compared to traditional therapies like chemotherapy and radiation. Applications span across treating different cancer stages and types, reflecting a broad end-use scope in oncology departments and advanced clinical research facilities globally. Market growth is primarily fueled by advancements in biotechnology, increasing prevalence of cancer, and growing investment in research and development by healthcare institutions. A significant opportunity arises from collaborations between biotech companies and research institutions, fostering innovative product development and paving the way for customized cancer vaccines. Companies are encouraged to focus on innovation around personalized medicine and to explore partnerships with AI technology providers to enhance vaccine development processes. Conversely, market growth is challenged by high development costs, stringent regulatory landscapes, and limited awareness in some parts of the world. Moreover, the complexity of clinical trials and variability in patient response also pose significant hurdles. However, emerging markets hold untapped potential due to their expanding healthcare infrastructure and increasing cancer prevalence. Innovative research areas include enhancing vaccine efficacy through combination therapies and the use of nanotechnology in vaccine formulation. The market, inherently dynamic and rapidly evolving, presents substantial growth possibilities for businesses that invest in cutting-edge research, strategic collaborations, and efficient supply chain management. By addressing these opportunities and overcoming the existing barriers, companies can effectively contribute to advancing cancer treatment modalities and improving patient outcomes globally.

KEY MARKET STATISTICS
Base Year [2023] USD 350.06 million
Estimated Year [2024] USD 392.59 million
Forecast Year [2030] USD 826.49 million
CAGR (%) 13.05%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dendritic Cell Cancer Vaccine Market

The Dendritic Cell Cancer Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer cases worldwide
    • Continuous advancements in immunotherapy and personalized medicines
  • Market Restraints
    • High cost of development of dendritic cell vaccine technology
  • Market Opportunities
    • Rising research and development efforts in the field of dendritic cell biology and vaccine technology
    • Supportive regulatory frameworks for accelerating the development of cancer therapies
  • Market Challenges
    • Limited awareness associated with benefits of dendritic cell vaccine technology

Porter's Five Forces: A Strategic Tool for Navigating the Dendritic Cell Cancer Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dendritic Cell Cancer Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dendritic Cell Cancer Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dendritic Cell Cancer Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dendritic Cell Cancer Vaccine Market

A detailed market share analysis in the Dendritic Cell Cancer Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dendritic Cell Cancer Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dendritic Cell Cancer Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dendritic Cell Cancer Vaccine Market

A strategic analysis of the Dendritic Cell Cancer Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dendritic Cell Cancer Vaccine Market, highlighting leading vendors and their innovative profiles. These include Aduro Biotech, APAC Biotech, Argos Therapeutics, Batavia Biosciences B.V., Creative Biolabs, Dendreon Pharmaceuticals, GSK PLC, ImmunoCellular Therapeutics, JW CreaGene, Northwest Biotherapeutics, Northwest Biotherapeutics, Inc., and Nouscom.

Market Segmentation & Coverage

This research report categorizes the Dendritic Cell Cancer Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cancer Type, market is studied across Breast Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, and Prostate Cancer.
  • Based on End-use, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer cases worldwide
      • 5.1.1.2. Continuous advancements in immunotherapy and personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development of dendritic cell vaccine technology
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising research and development efforts in the field of dendritic cell biology and vaccine technology
      • 5.1.3.2. Supportive regulatory frameworks for accelerating the development of cancer therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness associated with benefits of dendritic cell vaccine technology
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Cancer Type: Rising potential of dendritic cell cancer vaccine for prostate cancer that can specifically target cancer cells
    • 5.2.2. End-use: Rising usage of dendritic cell cancer vaccine across hospitals due to their comprehensive care facilities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dendritic Cell Cancer Vaccine Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Breast Cancer
  • 6.3. Liver Cancer
  • 6.4. Lung Cancer
  • 6.5. Ovarian Cancer
  • 6.6. Pancreatic Cancer
  • 6.7. Prostate Cancer

7. Dendritic Cell Cancer Vaccine Market, by End-use

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Research Institutes
  • 7.4. Specialty Clinics

8. Americas Dendritic Cell Cancer Vaccine Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Dendritic Cell Cancer Vaccine Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Dendritic Cell Cancer Vaccine Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aduro Biotech
  • 2. APAC Biotech
  • 3. Argos Therapeutics
  • 4. Batavia Biosciences B.V.
  • 5. Creative Biolabs
  • 6. Dendreon Pharmaceuticals
  • 7. GSK PLC
  • 8. ImmunoCellular Therapeutics
  • 9. JW CreaGene
  • 10. Northwest Biotherapeutics
  • 11. Northwest Biotherapeutics, Inc.
  • 12. Nouscom

LIST OF FIGURES

  • FIGURE 1. DENDRITIC CELL CANCER VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DENDRITIC CELL CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DENDRITIC CELL CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DENDRITIC CELL CANCER VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DENDRITIC CELL CANCER VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. DENDRITIC CELL CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 105. DENDRITIC CELL CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023